Methods: This double-blind, case-control trial was carried out on 73 leukemic and lymphoma patients who underwent chemotherapy. Patients in the case group were administered one 220 zinc sulfate capsule daily until one week after the end of their chemotherapy treatment. Two weeks after starting chemotherapy and three months after its ending, severity and quantity of pain were checked and recorded in both groups. Data were analyzed by ANOVA test.
Results: The mean and standard deviation of mucositis severity was 1.1±0.2 in the case group and 2.7±0.3 in control group, and there was a significant difference between case and control groups (P=0.00). The mean and standard deviation of VAS in case group was 2±2.52 and 6.2±3.6 in control group two weeks after treatment. There was a significant difference between case and control groups (P=0.00). Three months after the end of chemotherapy, the mean and standard deviation of mucositis severity was 0.5±0.03 in case group and 1.5±0.3 in control group and there was a significant difference between case and control groups (P=0.00). The mean and standard deviation of VAS in case group was 5.5±0.7 and 1.5±0.7 in control group. There was a significant difference between case and control groups (P=0.00).
Conclusions: It can be concluded that zinc sulfate might decrease the intensity of mucositis.